Atazanavir, Alone or in Combination with Ritonavir, Inhibits SARS-CoV-2 Replication and Proinflammatory Cytokine Production

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is already responsible for far more deaths than previous pathogenic coronaviruses (CoVs) from 2002 and 2012. The identification of clinically approved drugs to be repurposed to combat 2019 CoV disease (COVID-19) would allow the rapid imple...

Descripción completa

Detalles Bibliográficos
Autores principales: Fintelman-Rodrigues, Natalia, Sacramento, Carolina Q., Ribeiro Lima, Carlyle, Souza da Silva, Franklin, Ferreira, André C., Mattos, Mayara, de Freitas, Caroline S., Cardoso Soares, Vinicius, da Silva Gomes Dias, Suelen, Temerozo, Jairo R., Miranda, Milene D., Matos, Aline R., Bozza, Fernando A., Carels, Nicolas, Alves, Carlos Roberto, Siqueira, Marilda M., Bozza, Patrícia T., Souza, Thiago Moreno L.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Society for Microbiology 2020
Materias:
Antiviral Agents
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508582/
https://www.ncbi.nlm.nih.gov/pubmed/32759267
http://dx.doi.org/10.1128/AAC.00825-20

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7508582/
https://www.ncbi.nlm.nih.gov/pubmed/32759267
http://dx.doi.org/10.1128/AAC.00825-20

Ejemplares similares